China Pharma Holdings Inc(CPHI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 8:10 AM ET (Korea 10/27 21:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.42 | Insider Own | 6.23% | Shs Outstand | 40.5M | Perf Week | -7.34% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 40.3M | Perf Month | -15.54% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 0.47% | Short Float | 0.15% | Perf Quarter | -51.17% |
| Income | -0.00B | P/S | 6.98 | EPS this Y | - | Inst Trans | 479.65% | Short Ratio | 0.03 | Perf Half Y | 7.92% |
| Sales | 0.00B | P/B | 0.71 | EPS next 5Y | - | ROA | -15.21% | Short Interest | 0.06M | Perf YTD | -47.54% |
| Book/sh | 0.9 | P/C | 88.09 | EPS past 3/5Y | 73.01% 53.14% | ROE | -20.81% | 52W High | -96.69% ($19.19) | Perf Year | -65.04% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | -20.03% -17.53% | ROIC | -12.28% | 52W Low | 66.27% ($0.38) | Perf 3Y | -88.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.83% | Gross Margin | -47.35% | Volatility(W/M) | 6.81% 16.9% | Perf 5Y | -99.8% |
| Dividend TTM | - | EV/Sales | 7.91 | Sales Y/Y TTM | -10.97% | Oper. Margin | -111.84% | ATR (14) | 0.11 | Perf 10Y | -99.37% |
| Dividend Ex-Date | - | Quick Ratio | 0.08 | EPS Q/Q | 77.78% | Profit Margin | -114.33% | RSI (14) | 40.37 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.26 | Sales Q/Q | -7.55% | SMA20 | -12.12% ($0.72) | Beta | 0.95 | Target Price | - |
| Payout | - | Debt/Eq | 0.11 | Earnings | - | SMA50 | -19.84% ($0.79) | Rel Volume | 0.03 | Prev Close | $0.66 |
| Employees | 221 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -24.97% ($0.84) | Avg Volume(3M) | 1.97M | Price | $0.63 |
| IPO | 2002/4/17 | Option/Short | No/Yes | Trades | 116 | Volume | 55,076 | Change | -3.61% |
💊 China Pharma Holdings is a U.S.-listed, China-based small-cap pharmaceutical company that manufactures and sells generic and specialty drugs through its subsidiary **Hainan Helpson**, located in Haikou, Hainan Province, China. It produces injectables, tablets, capsules, and cephalosporin oral formulations targeting cardiovascular, central nervous system, infectious, and gastrointestinal disease areas, and is also working on the commercialization of a medical device for treating dry eye syndrome. It is a micro-cap stock listed on the NYSE American.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
CPHI has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $698. Peers typically go for $197.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.5%.
Tap to view numbers
It ranks #66 of 83 in the industry
Based on market cap of $27M.
IXHL#64 Incannex Healthcare Inc $33M PER - 
RMTI#65 Rockwell Medical Inc $28M PER - CPHI#66 China Pharma Holdings Inc $27M PER - 
SHPH#67 Shuttle Pharmaceuticals Holdings Inc $24M PER - 
AYTU#68 Aytu BioPharma Inc $21M PER - 
FAQ
What kind of company is CPHI?
CPHI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CPHI?
The market cap of CPHI is approximately $27M, ranking 5,105 within its sector.
What is the 52-week high and low for CPHI?
CPHI has recorded a 52-week high of $19.19 and a low of $0.38.
